PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure;Influence sur les résultats des rebonds du PSA après curiethérapie de prostate : étude de 295 cas avec trois ans de suivi

Cancer/Radiotherapie

Volumn 11, Issue 3, 2007, Pages 105-110

  Toledano, A ^a   Chauveinc, L ^b   Flam, T ^c   Thiounn, N ^d   Solignac, S ^e   Timbert, M ^e   Rosenwald, J C ^e   Cosset, J M ^e  

^a HÔPITAL TENON   (France)

^b Clinique Hartmann   (France)

^c hôpital Cochin ^*  (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSTITUT CURIE   (France)

Author keywords

Bounce; Brachytherapy; Prostate cancer; PSA

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RELAPSE; DOSIMETRY; FOLLOW UP; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; AGE; BLOOD; MIDDLE AGED; PROSTATE TUMOR;

AGE FACTORS; AGED; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 34248674120     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2006.10.005     Document Type: Article

References (36)

1. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 37 (1997) 1035-1041
2. Berruti A., Dogliotti L., Terrone C., Cerutti S., Isaia G., Tarabuzzi R., et al. Changes in bone density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J. Urol. 167 (2002) 2361-2367
3. Blasko J.C., Wallner K., Grimm P.D., and Ragde H. Prostate specific based disease control following ultrasond guided 125iodine implantation for stage T1-T2 prostatic carcinoma. J. Urol. 154 (1995) 1096-1099
4. Buyyounousky M.K., Hanlon A.L., and Pollack A. The temporal kinetics of PSA after 3D-conformal radiotherapy with androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 147
5. Cavanagh W., Blasko J.C., Grimm P.D., and Sylvester J.E. Transient elevation of serum prostate-specific antigen following (125)I/ (103)Pd brachytherapy for localized prostate cancer. Semin. Urol. Oncol. 18 (2000) 160-165
6. Chauveinc L., Flam T., Solignac S., Thiounn N., Firmin F., Debre B., et al. Prostate cancer brachytherapy: is real-time ultrasound-based dosimetry predictive of subsequent CT-based dose distribution calculation? A study of 450 patients by Institute Curie-Hospital Cochin (Paris) group. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 691-695
7. Chauveinc L., Osseili A., Flam T., Thiounn N., Rosenwald J.C., Savignoni A., et al. Iodin 125 seed migration after prostate brachytherapy: a study of 170 patients. Cancer Radiother. 8 (2004) 211-216
8. Chauveinc L., Flam T., Solignac S., Rosenwald J.C., Thiounn N., Firmin F., et al. Indications for curietherapy of the prostate using permanent implants. Cancer Radiother. 6 (2002) 154-158
9. Chauveinc L., Salem N., Pommier P., Peiffert D., Guerif S., Hannoun-Levy J.M., et al. Groupe des utilisateurs de la curiethérapie à implantation permanente pour les cancers de la prostate. Brachytherapy of the prostatic cancer by interstitial permanent implantation of iodine-125. Cancer Radiother. 6 (2002) 112-115
10. Cosset J.M., Flam T., Thiounn N., Rosenwald J.C., and Chauveinc L. La curiethérapie du cancer prostatique : un état des lieux en 2004. Oncologie 6 (2004) 422-427
11. Critz F.A., Williams W.H., Benton J.B., Levinson A.K., Holladay C.T., and Holladay D.A. Prostate specific antigen bounces after radioactive seed implantation followed by external beam radiation for prostate cancer. J. Urol. 163 (2000) 1085-1089
12. Das P., Chen M.H., Valentine K., Lopes L., Cormack R.A., Renshaw A.A., et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 698-702
13. Grimm P., Blasko J., Sylvester J., Meier R.M., and Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 31-40
14. Hanlon A.L., Pinover W.H., Horwitz E.M., and Hanks G.E. Patterns and fate of PSA bouncing following 3D-CRT. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 845-849
15. Hinerman-Mulroy A., Merrick G.S., Butler W.M., Wallner K.E., Allen Z., and Adamovich E. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 1367-1382
16. 125I radioactive seed implantation in the treatment of T1-T2 prostate cancer. Radiat. Oncol. Invest. 7 (1999) 30-35
17. Killian C.S., Yang N., Emrich L.J., Vargas R.P., Kuriyama M., Wang M.C., et al. Prognostic importance of prostate-specific antigen for monitoring patients with stage B2 to D1 prostate cancer. Cancer Res. 45 (1985) 886-891
18. Kucway R., Vicini F., Huang R., Stromberg J., Gonzales J., and Martinez A. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J. Urol. 167 (2002) 2443-2447
19. Lee W.R., Moughan J., Owen J.B., and Zelefsky M.J. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Cancer 98 (2003) 1987-1994
20. Merrick G.S., Butler W.M., Wallner K.D., Galbreath R.W., and Anderson R.L. Prostate-specific antigen spikes after permanent brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 450-456
21. Merrick G.S., Butler W.M., Wallner K.D., Galbreath R.W., Allen Z., and Adamovich E. Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. Brachytherapy 3 (2004) 141-146
22. Nag S., Beyer D., Friedland D., Grimm P., and Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 44 (1999) 789-799
23. Nag S., Gezki J.P., Cormak R., Doggett S., DeWingaert K., Edmundson G.K., et al. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 1422-1430
24. Nag S., Ellis R.J., Merrick G.S., Bahnson R., Wallner K., Stock R., et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 462-470
25. Oesterling J.E., Chan D.W., Epstein J.I., Kimball A.W., Bruzek D.J., Rock R.C., et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139 (1988) 766-772
26. Patel C., Elshaikh M.A., Angermeier K., Ulchaker J., Klein F.A., Chehade N., et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 63 (2004) 110-113
27. Potters L., Torre T., Ashley R., and Leibel S. Examining the role of neoadjuvant androgen deprivation in-patient undergoing prostate brachytherapy. J. Clin. Oncol. 18 (2000) 1187-1192
28. Pruthi R.S. Editorial: Re.Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J. Urol. 154 (2000) 2031
29. Roach III M., Hanks G., Thames Jr. H., Schellhammer P., Shipley W.U., Sokol G.H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 65 (2006) 965-974
30. Rosser C.J., Kuban D.A., Levy L.B., Chichakli R., Pollack A., Lee A.K., et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J. Urol. 168 (2002) 2001-2005
31. Sengoz M., Abacioglu U., Cetin I., and Turkeri L. PSA bouncing after external beam radiation for prostate cancer with or without hormonal treatment. Eur. Urol. 43 (2003) 473-477
32. 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int. J. Radiat. Oncol. Biol. Phys. 50 (2001) 335-341
33. Stock R.G., Kao J., and Stone N.N. Penile erectile function following permanent radioactive seed implantation for the treatment of prostate cancer. J. Urol. 165 (2001) 436-439
34. Stock R.G., Stone N.N., and Cesaretti J.A. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int. J. Radiat. Oncol. Biol. Phys. 56 (2003) 448-453
35. Toledano A., Chauveinc L., Flam T., Thiounn N., Solignac S., Timbert M., et al. PSA bouncing after permanent implant prostate brachytherapy: a study of 295 patients with a three-year follow-up. Brachytherapy 5 (2006) 122-126
36. Zelefsky M.J. Three-dimensional conformal brachytherapy for prostate cancer. Curr. Urol. Rep. 5 (2004) 173-178